TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9748717

Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg capsule (Cefzon)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg daily for 3 to 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefdinir 200 mg (2 capsules) daily for 4 to 14 consecutive days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 12
Study: 8164860

Group type: EXPERIMENTAL
Intervention: Early ankle mobilization (elastic wrap or air-stirrup)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Elastic wrap
Number of subjects: 64
Study: 2971515

Group type: EXPERIMENTAL
Intervention: salbutamol, 5 mg mixed with ipratropium bromide 500 micrograms
Number of subjects: 40

Group type: COMPARATOR
Intervention: salbutamol, 5 mg
Number of subjects: 40
Study: 12402423

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of IL-2 and IFN-alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Addition of other cytokines (e.g., GM-CSF) or chemotherapy
Number of subjects: 0
Study: 30841688

Group type: EXPERIMENTAL
Intervention: Barrett calculator
Number of subjects: 64

Group type: COMPARATOR
Intervention: AcrySof calculator
Number of subjects: 64
Study: 29656500

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) for six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strength training (ST) for six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined three-month ST+TRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26409243

Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM) graft
Number of subjects: 499

Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cells (PBSC) graft
Number of subjects: 499
Study: 24832980

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 37
Study: 21638162

Group type: EXPERIMENTAL
Intervention: Aquamid® filler, 8 ml per session, retreated every 8 weeks until full correction observed.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Aquamid® filler, 2 ml per session, retreated every 8 weeks until full correction observed.
Number of subjects: 31
Study: 19553067

Group type: EXPERIMENTAL
Intervention: Assertive continuing care
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard continuing care
Number of subjects: 342
Study: 18813866

Group type: COMPARATOR
Intervention: 600 mg of Shoyu polysaccharides (SPS) daily for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 600 mg of Shoyu polysaccharides (SPS) daily for 4 weeks
Number of subjects: 20
Study: 15755232

Group type: EXPERIMENTAL
Intervention: Extensively personalized booklet
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Minimally personalized booklet
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard booklet
Number of subjects: 240
Study: 12464889

Group type: EXPERIMENTAL
Intervention: Maxillary distraction osteogenesis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional maxillary advancement
Number of subjects: 18
Study: 10622347

Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg
Number of subjects: 228

Group type: COMPARATOR
Intervention: Risperidone 8 mg
Number of subjects: 228
Study: 7594026

Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 210
Study: 1952008

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate ointment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Eutectic mixture of local anaesthetics cream
Number of subjects: 104
Study: 6764162

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31687933

Group type: EXPERIMENTAL
Intervention: Novel paclitaxel-coated drug-coated balloon (DCB)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Uncoated plain old balloon angioplasty (POBA)
Number of subjects: 171
Study: 30850310

Group type: EXPERIMENTAL
Intervention: It's Your Game…Keep It Real program
Number of subjects: 1693
Study: 29855986

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (120 mg, twice a day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Pentoxifylline (600 mg, twice a day)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 197

Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 197
Study: 26498455

Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2314
Study: 24794703

Group type: EXPERIMENTAL
Intervention: Insulin analogues (detemir and aspart)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Human insulin (human neutral protamine Hagedorn and human regular)
Number of subjects: 141
Study: 22045363

Group type: EXPERIMENTAL
Intervention: Midodrine (alpha agonist)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 19551459

Group type: EXPERIMENTAL
Intervention: Lactose-[(13)C]ureide breath test (LUBT) with 2 g of lactose-[(13)C]ureide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glucose hydrogen breath test (GHBT) with 50 g glucose
Number of subjects: 22
Study: 17461529

Group type: EXPERIMENTAL
Intervention: Gynoplus (black cohosh and St. John's wort)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 14604623

Group type: EXPERIMENTAL
Intervention: Communication strategies developed to assist doctors in seeking informed consent to cancer clinical trials.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training package based on developed communication strategies.
Number of subjects: 26
Study: 12884566

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) program
Number of subjects: 27
Study: 9523208

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIDDM
Number of subjects: 0
Study: 8602384

Group type: EXPERIMENTAL
Intervention: Nephrotoxic chemotherapy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Nonnephrotoxic chemotherapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no cancer)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Age effect on pharmacokinetics
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Gentamicin dosing
Number of subjects: 77
Study: 2669222

Group type: EXPERIMENTAL
Intervention: Low dose nebulised morphine (5 ml of morphine 1 mg/ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 11
Study: 769773

Group type: EXPERIMENTAL
Intervention: Active electrosleep therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated treatment (placebo)
Number of subjects: 0
Study: 31596174

Group type: EXPERIMENTAL
Intervention: Peer support program for glycemic management
Number of subjects: 0
Study: 28647167

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT vaccine
Number of subjects: 94
Study: 26081587

Group type: EXPERIMENTAL
Intervention: 40 mg of telmisartan
Number of subjects: 300

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 300
Study: 23832086

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 34
Study: 21528641

Group type: EXPERIMENTAL
Intervention: Test formulation of mosapride citrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of mosapride citrate
Number of subjects: 20
Study: 18648237

Group type: EXPERIMENTAL
Intervention: L4-L5 primary dorsal rami and S1-S3 lateral branch radiofrequency denervation using cooling-probe technology after a local anesthetic block
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo denervation after local anesthetic block
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Crossover group (patients who did not respond to placebo) treated with radiofrequency denervation using conventional technology
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 28
Study: 16424446

Group type: EXPERIMENTAL
Intervention: Transtracheal open ventilation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional invasive ventilation
Number of subjects: 39
Study: 12837869

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10877005

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Citalopram (40 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9413817

Group type: EXPERIMENTAL
Intervention: Teacher high-level questions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Teacher elaboration of student ideas
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Teacher probing questions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Student participation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Student-to-student participation
Number of subjects: 57
Study: 8493803

Group type: COMPARATOR
Intervention: Amino‐Mel hepa (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amino‐Mel hepa + L‐valine (Group B)
Number of subjects: 30
Study: 3522443

Group type: EXPERIMENTAL
Intervention: 1g of ambroxol for three days before surgery, on the day of the operation and for five days afterwards
Number of subjects: 40
Study: 30264583

Group type: EXPERIMENTAL
Intervention: Smart Glucose Manager (SGM) application
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (standard methods of diabetes management)
Number of subjects: 67
Study: 27662264

Group type: EXPERIMENTAL
Intervention: New oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single-dose oral liquid formulation (5 to 15 mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple dosing of oral liquid formulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: New oral liquid formulation
Number of subjects: 12
Study: 25546568

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) with the InterStim® System
Number of subjects: 272
Study: 23338666

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 60
Study: 23092665

Group type: EXPERIMENTAL
Intervention: Intravenous PPI followed by oral administration (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral PPIs alone (group 1)
Number of subjects: 40
Study: 20021657

Group type: EXPERIMENTAL
Intervention: Oral artesunate (AS) 2-5 mg/kg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Oral artesunate (AS)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (DHA)
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-fat and high-caloric meal prior to drug administration
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 91
Study: 18030711

Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis (cell transplantation, gene therapy, application of growth factors)
Number of subjects: 0
Study: 12547365

Group type: EXPERIMENTAL
Intervention: Strength-Dexterity (S-D) test using a subset of 39 springs
Number of subjects: 42

Group type: COMPARATOR
Intervention: Maximal pinch force values
Number of subjects: 42
Study: 10924866

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 or 3000 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 8810671

Group type: EXPERIMENTAL
Intervention: Reumalex, a licensed over-the-counter herbal medicine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 1605451

Group type: EXPERIMENTAL
Intervention: Defibrotide (DF) 400 mg i.v. given one hour prior to operation and twice daily for seven days postoperatively
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Calcium-heparin (CH) 0.2 ml (5000 U.I.) subcutaneously given one hour prior to operation and twice daily for seven days postoperatively
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Defibrotide (DF)
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Calcium-heparin (CH)
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1212
Study: 6420352

Group type: EXPERIMENTAL
Intervention: Sustained release buccal nitroglycerin (23.4 mg daily)
Number of subjects: 21
Study: 3716918

Group type: EXPERIMENTAL
Intervention: Four hypnotic sessions with a booster
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Two hypnotic sessions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Two hypnotic and two behavioral sessions with a booster
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Four hypnotic sessions and a booster session (follow-up group)
Number of subjects: 63
Study: 29166778

Group type: EXPERIMENTAL
Intervention: Autogenic relaxation CD
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 26851251

Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training of the operated leg two days/week in addition to home‐based exercise five days/week for 10 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Progressive resistance training with increasing load from 12 repetition maximum to 8 repetition maximum over 10 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 37
Study: 25708324

Group type: EXPERIMENTAL
Intervention: Divaza preparation, 12-week treatment course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22130178

Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 20456149

Group type: EXPERIMENTAL
Intervention: Behavioral Training (BT)
Number of subjects: 13
Study: 18376267

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propofol and fentanyl
Number of subjects: 22
Study: 16724578

Group type: EXPERIMENTAL
Intervention: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after a fat-rich breakfast (Treatment A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (Neoral, Novartis AG, Basel, Switzerland, 200 mg) after a fat-rich breakfast (Treatment B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after fasting (Treatment C)
Number of subjects: 18
Study: 12774949

Group type: EXPERIMENTAL
Intervention: Anticonvulsants (AC Group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No anticonvulsants (No AC Group)
Number of subjects: 100
Study: 10752808

Group type: EXPERIMENTAL
Intervention: Enteral feed enriched with arginine, mRNA, and omega‐3 fatty acids from fish oil (Impact)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Common use, high protein control feed (Precitene Hiperproteico)
Number of subjects: 181
Study: 9172210

Group type: EXPERIMENTAL
Intervention: Nondirective suggestions as pretreatment (20 min tape with pain theory and coping suggestions)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 48
Study: 1603650

Group type: EXPERIMENTAL
Intervention: Variable pulse rate condition (randomly varying pulse rates from trial to trial)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Constant pulse rate condition (pulse rates were constant within trial blocks)
Number of subjects: 944
Study: 4005120

Group type: EXPERIMENTAL
Intervention: 10/170 Oros oxprenolol succinate (170 mg, initial release rate 10 mg/h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16/260 Oros oxprenolol succinate (260 mg, initial release rate 16 mg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow Trasicor (160 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trasicor (80 mg twice daily)
Number of subjects: 0
Study: 30804818

Group type: EXPERIMENTAL
Intervention: Mobile app-based intervention (treatment as usual plus five modules: psychoeducation, recognition of symptoms and prevention of relapses, problem solving, mindfulness, and contact wall)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile app-based intervention
Number of subjects: 0
Study: 28853029

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 12 weeks, 4 x 4-min bouts at 85-95% HRmax, 3 times/week, with nutrition advice
Number of subjects: 99

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) - 12 weeks, 44 min at 60-70% HRmax, 3 times/week, with nutrition advice
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nutrition advice only
Number of subjects: 99
Study: 27746007

Group type: EXPERIMENTAL
Intervention: Amoxicillin and metronidazole for 5 days postoperatively
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (identical-looking drugs)
Number of subjects: 150
Study: 24670891

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study: 22879421

Group type: EXPERIMENTAL
Intervention: Intravitreal ocriplasmin
Number of subjects: 652
Study: 20538819

Group type: EXPERIMENTAL
Intervention: CUE intervention (visually standardized, interpreted peak flow graphs)
Number of subjects: 0
Study: 18166569

Group type: EXPERIMENTAL
Intervention: High-energy and protein diet (120% recommended average intake)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Average energy and protein diet (100% recommended average intake)
Number of subjects: 16
Study: 16130424

Group type: EXPERIMENTAL
Intervention: Therapeutic-and-prophylactic care delivered at the 'Zhemchuzhina' tuberculosis sanatorium
Number of subjects: 390
Study: 12860216

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 to 80 mg
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 to 40 mg
Number of subjects: 2431

Group type: COMPARATOR
Intervention: atorvastatin 10 to 80 mg
Number of subjects: 2431

Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 2431
Study: 10651663

Group type: EXPERIMENTAL
Intervention: LAM-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 2 weeks)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: LAM-1 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 1 week and placebo)
Number of subjects: 228

Group type: COMPARATOR
Intervention: LA-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and placebo for 2 weeks)
Number of subjects: 228
Study: 9125301

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 23
Study: 1386976

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ondansetron 12 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 39
Study: 6384452

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg/day intravenously for three doses)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no furosemide)
Number of subjects: 57
Study: 31832291

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily orally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 40
Study: 28667486

Group type: EXPERIMENTAL
Intervention: Staff-training intervention focusing on skills for engaging service users in activities
Number of subjects: 23

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 23
Study: 24595923

Group type: EXPERIMENTAL
Intervention: Bevacizumab (100 mg, intranasal submucosal injection, 10 mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 15
Study: 24973295

Group type: EXPERIMENTAL
Intervention: Partial thickness mucosal flap
Number of subjects: 22

Group type: COMPARATOR
Intervention: Full thickness mucoperiosteal flap
Number of subjects: 22
Study: 22993917

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous iliofascial block (CIFB)
Number of subjects: 60
Study: 19013573

Group type: EXPERIMENTAL
Intervention: Dietary intervention with Okinawan vegetables for 2 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 45
Study: 17223475

Group type: EXPERIMENTAL
Intervention: Pulses of vincristine (1.5 mg/m2 weekly for 2 weeks) and dexamethasone (6 mg/m2 daily for 7 days) every 10 weeks for six cycles
Number of subjects: 2935

Group type: COMPARATOR
Intervention: Conventional mercaptopurine and methotrexate chemotherapy only
Number of subjects: 2935

Group type: EXPERIMENTAL
Intervention: Pulses of vincristine and dexamethasone
Number of subjects: 2935
Study: 15073858

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: BCG plus dacarbazine
Number of subjects: 734

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 734
Study: 11583749

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b 1.5 microg/kg each week plus 800 mg/day ribavirin
Number of subjects: 1530
Study: 9040298

Group type: EXPERIMENTAL
Intervention: Home Access Health Corp HIV-1 test system
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Traditional venous blood testing
Number of subjects: 1255
Study: 8200265

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3322824

Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: Inhalational anaesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: Artificial ventilation
Number of subjects: 38